TABLE 1.
Compared characteristics of wild-type control and heterozygote cases.
| All subjects(N = 136) | GG (N = 68) | GA (N = 68) | p# | Odds ratio (95%CI) | |
|---|---|---|---|---|---|
| Patients characteristic | |||||
| Male (%) | 112/136 (82.35) | 55/68 (80.88) | 57/68 (83.82) | 0.822 | - |
| Age, years | 44.32 ± 11.18 | 44.56 ± 11.75 | 44.08 ± 10.66 | 0.428 | - |
| Patients using ETV (%) | 110/136 (80.88) | 20/55 (36.36) | 20/55 (36.36) | 1.000 | - |
| ♣Baseline | |||||
| HBV DNA, log10 IU/mL | 5.94 ± 1.69 | 5.79 ± 1.76 | 6.09 ± 1.62 | 0.220 | - |
| HBsAg, IU/ml | 5114.59 ± 9383.31 | 5373.11 ± 9709.35 | 6140.06 ± 11503.98 | 0.753 | - |
#p - value between GG and GA group. Significant p-value in bold (threshold p < 0.05)
♣The latest laboratory test results before initiation of NAs treatment was defined as baseline